DK1098643T3 - Phenylacetylglutamin, phenylacetylisoglutamin og/eller phenylacetat til behandling af neoplastiske sygdomme - Google Patents

Phenylacetylglutamin, phenylacetylisoglutamin og/eller phenylacetat til behandling af neoplastiske sygdomme

Info

Publication number
DK1098643T3
DK1098643T3 DK99932179T DK99932179T DK1098643T3 DK 1098643 T3 DK1098643 T3 DK 1098643T3 DK 99932179 T DK99932179 T DK 99932179T DK 99932179 T DK99932179 T DK 99932179T DK 1098643 T3 DK1098643 T3 DK 1098643T3
Authority
DK
Denmark
Prior art keywords
phenylacetylisoglutamine
phenylacetylglutamine
phenylacetate
pharmaceutical composition
treatment
Prior art date
Application number
DK99932179T
Other languages
Danish (da)
English (en)
Inventor
Stanislaw R Burzynski
Original Assignee
Stanislaw R Burzynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw R Burzynski filed Critical Stanislaw R Burzynski
Application granted granted Critical
Publication of DK1098643T3 publication Critical patent/DK1098643T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK99932179T 1998-07-23 1999-07-02 Phenylacetylglutamin, phenylacetylisoglutamin og/eller phenylacetat til behandling af neoplastiske sygdomme DK1098643T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (1)

Publication Number Publication Date
DK1098643T3 true DK1098643T3 (da) 2004-05-24

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99932179T DK1098643T3 (da) 1998-07-23 1999-07-02 Phenylacetylglutamin, phenylacetylisoglutamin og/eller phenylacetat til behandling af neoplastiske sygdomme

Country Status (20)

Country Link
US (2) US6258849B1 (https=)
EP (1) EP1098643B1 (https=)
JP (2) JP2002521329A (https=)
KR (4) KR100417101B1 (https=)
CN (3) CN1191064C (https=)
AT (1) ATE257378T1 (https=)
AU (1) AU759278B2 (https=)
BR (1) BR9912356A (https=)
CA (1) CA2336945C (https=)
DE (1) DE69914084T2 (https=)
DK (1) DK1098643T3 (https=)
EA (1) EA004179B1 (https=)
ES (1) ES2214866T3 (https=)
ID (1) ID28160A (https=)
IL (1) IL140848A (https=)
NZ (1) NZ509244A (https=)
PL (1) PL213698B1 (https=)
PT (1) PT1098643E (https=)
WO (1) WO2000004894A2 (https=)
ZA (1) ZA200100622B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
WO2002018324A2 (en) 2000-08-29 2002-03-07 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
US20060058383A1 (en) * 2004-07-28 2006-03-16 Peng Huang Propyl 3-bromo-2-oxopropionate and derivatives as novel anticancer agents
SG158073A1 (en) * 2004-11-26 2010-01-29 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
CA2757373C (en) 2009-04-03 2018-05-08 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
EA201691430A1 (ru) 2009-06-08 2017-02-28 ЮСиЭл БИЗНЕС ПиЭлСи Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата
MX360062B (es) 2010-10-06 2018-10-22 Ocera Therapeutics Inc Metodos de elaboracion de fenilacetato de l-ornitina.
US10039735B2 (en) 2014-11-24 2018-08-07 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
WO2017114686A1 (en) * 2015-12-30 2017-07-06 Nestec S.A. Method for determining fat free body mass
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
WO2018208677A1 (en) 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Processes of making l-ornithine phenylacetate
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
AU2018282735A1 (en) * 2017-06-12 2020-02-06 Stanislaw R. Burzynski Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
EP4731793A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating pancreatic cancer
EP4731792A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating lung cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5244922A (en) 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ATE310505T1 (de) 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Also Published As

Publication number Publication date
CN1660061A (zh) 2005-08-31
CN1605334A (zh) 2005-04-13
CA2336945C (en) 2008-11-18
EA200100168A1 (ru) 2001-08-27
NZ509244A (en) 2004-02-27
WO2000004894A3 (en) 2000-04-27
HK1037142A1 (en) 2002-02-01
DE69914084D1 (de) 2004-02-12
PT1098643E (pt) 2004-05-31
US6943192B2 (en) 2005-09-13
PL213698B1 (pl) 2013-04-30
KR100417100B1 (ko) 2004-02-05
KR100414587B1 (ko) 2004-01-13
IL140848A (en) 2005-05-17
AU4854299A (en) 2000-02-14
ES2214866T3 (es) 2004-09-16
JP2011051993A (ja) 2011-03-17
KR20030027088A (ko) 2003-04-03
ID28160A (id) 2001-05-10
US20010044466A1 (en) 2001-11-22
CN1191064C (zh) 2005-03-02
KR100417101B1 (ko) 2004-02-05
DE69914084T2 (de) 2004-10-28
AU759278B2 (en) 2003-04-10
KR20030027087A (ko) 2003-04-03
KR20030027089A (ko) 2003-04-03
ZA200100622B (en) 2002-06-26
EA004179B1 (ru) 2004-02-26
IL140848A0 (en) 2002-02-10
KR20010071025A (ko) 2001-07-28
CN100400039C (zh) 2008-07-09
CN1319010A (zh) 2001-10-24
BR9912356A (pt) 2001-04-17
EP1098643B1 (en) 2004-01-07
EP1098643A2 (en) 2001-05-16
WO2000004894A2 (en) 2000-02-03
JP2002521329A (ja) 2002-07-16
ATE257378T1 (de) 2004-01-15
PL345959A1 (en) 2002-01-14
CA2336945A1 (en) 2000-02-03
US6258849B1 (en) 2001-07-10
KR100399658B1 (ko) 2003-09-29

Similar Documents

Publication Publication Date Title
DK1098643T3 (da) Phenylacetylglutamin, phenylacetylisoglutamin og/eller phenylacetat til behandling af neoplastiske sygdomme
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
DE69930739D1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
MA23170A1 (fr) Procede de preparation d'un nouveau compose .
UA42734C2 (uk) Водорозчинна сіль німеcуліду, водний розчин солі німеcуліду, композиції на основі німеcуліду, спосіб отримання водорозчинної солі німеcуліду та фармацевтична композиція для лікування запалювальних захворювань
DE60000288D1 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
BR9708388A (pt) Solução aquosa de hemoglobina polimerizada piridoxilada e processo de sua preparação.
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
KR960702313A (ko) 티아조푸린 및 리바비린을 사용하는 종양질환의 치료방법 (method for the treatment of neoplastic disease utilizing tlazofurin and ribavirin)
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
ATE86112T1 (de) Pharmazeutische zubereitung zur behandlung entzuendeter nasenschleimhaeute.
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
EA199901103A1 (ru) Антивирусный препарат для инъекций
NZ510776A (en) Method for preparing a solution for nasal spray containing sex hormones and a cyclodextrin
IT1229271B (it) Preparazione medicinale di un estratto delle radici di ortica, urtica kiovensis (rogowicz), suo impiego per il trattamento di tumori e processo di preparazione.
DE69630761D1 (de) Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten
DE69428797D1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
RU96122371A (ru) Способ лечения эндогенных и послеоперационных увеитов
DK0788355T3 (da) Anvendelse af intravenøst indgiveligt jern til behandling af tumorsygdomme og/eller infektionssygdomme